Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|4|665-679

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.4, 2013-02, pp. : 665-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimer's Disease

By  

Current Drug Targets, Vol. 7, Iss. 11, 2006-11 ,pp. : 1389-1397

Bentham Science Publishers

Access to resources Recommend Favorite

Design of Glycogen Synthase Kinase-3 Inhibitors: An Overview on Recent Advancements

By  

Current Pharmaceutical Design, Vol. 19, Iss. 26, 2013-08 ,pp. : 4755-4775

Bentham Science Publishers

Access to resources Recommend Favorite

Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 3, 2004-03 ,pp. : 439-443

Informa Healthcare

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?

By  

Current Cancer Drug Targets, Vol. 7, Iss. 3, 2007-05 ,pp. : 209-215

Bentham Science Publishers

Access to resources Recommend Favorite